vs

Side-by-side financial comparison of Citi Trends Inc (CTRN) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Citi Trends Inc is the larger business by last-quarter revenue ($197.1M vs $127.1M, roughly 1.6× Zai Lab Ltd). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs 10.1%). Citi Trends Inc produced more free cash flow last quarter ($767.0K vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs -4.3%).

Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

CTRN vs ZLAB — Head-to-Head

Bigger by revenue
CTRN
CTRN
1.6× larger
CTRN
$197.1M
$127.1M
ZLAB
Growing faster (revenue YoY)
ZLAB
ZLAB
+7.1% gap
ZLAB
17.1%
10.1%
CTRN
More free cash flow
CTRN
CTRN
$27.5M more FCF
CTRN
$767.0K
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
-4.3%
CTRN

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CTRN
CTRN
ZLAB
ZLAB
Revenue
$197.1M
$127.1M
Net Profit
$-6.9M
Gross Margin
51.0%
Operating Margin
-3.7%
-54.6%
Net Margin
-3.5%
Revenue YoY
10.1%
17.1%
Net Profit YoY
3.6%
EPS (diluted)
$-0.86
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTRN
CTRN
ZLAB
ZLAB
Q4 25
$197.1M
$127.1M
Q3 25
$190.8M
$115.4M
Q2 25
$201.7M
$109.1M
Q1 25
$211.2M
$105.7M
Q4 24
$179.1M
$108.5M
Q3 24
$176.6M
$101.8M
Q2 24
$186.3M
$100.1M
Q1 24
$215.2M
$87.1M
Net Profit
CTRN
CTRN
ZLAB
ZLAB
Q4 25
$-6.9M
Q3 25
$3.8M
$-36.0M
Q2 25
$871.0K
$-40.7M
Q1 25
$-14.2M
$-48.4M
Q4 24
$-7.2M
Q3 24
$-18.4M
$-41.7M
Q2 24
$-3.4M
$-80.3M
Q1 24
$3.6M
$-53.5M
Gross Margin
CTRN
CTRN
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
CTRN
CTRN
ZLAB
ZLAB
Q4 25
-3.7%
-54.6%
Q3 25
1.8%
-42.3%
Q2 25
0.2%
-50.3%
Q1 25
0.6%
-53.3%
Q4 24
-4.9%
-62.6%
Q3 24
-14.1%
-66.6%
Q2 24
-3.7%
-76.0%
Q1 24
1.8%
-80.7%
Net Margin
CTRN
CTRN
ZLAB
ZLAB
Q4 25
-3.5%
Q3 25
2.0%
-31.2%
Q2 25
0.4%
-37.3%
Q1 25
-6.7%
-45.8%
Q4 24
-4.0%
Q3 24
-10.4%
-40.9%
Q2 24
-1.8%
-80.2%
Q1 24
1.7%
-61.4%
EPS (diluted)
CTRN
CTRN
ZLAB
ZLAB
Q4 25
$-0.86
$-0.05
Q3 25
$0.46
$-0.03
Q2 25
$0.11
$-0.04
Q1 25
$-1.70
$-0.04
Q4 24
$-0.86
$-0.09
Q3 24
$-2.21
$-0.04
Q2 24
$-0.42
$-0.08
Q1 24
$0.43
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTRN
CTRN
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$689.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$107.8M
$715.5M
Total Assets
$464.3M
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTRN
CTRN
ZLAB
ZLAB
Q4 25
$689.6M
Q3 25
$717.2M
Q2 25
$732.2M
Q1 25
$757.3M
Q4 24
$779.7M
Q3 24
$616.1M
Q2 24
$630.0M
Q1 24
$650.8M
Stockholders' Equity
CTRN
CTRN
ZLAB
ZLAB
Q4 25
$107.8M
$715.5M
Q3 25
$113.2M
$759.9M
Q2 25
$108.6M
$791.7M
Q1 25
$113.2M
$810.8M
Q4 24
$130.3M
$840.9M
Q3 24
$136.6M
$667.7M
Q2 24
$154.8M
$704.2M
Q1 24
$157.7M
$762.2M
Total Assets
CTRN
CTRN
ZLAB
ZLAB
Q4 25
$464.3M
$1.2B
Q3 25
$457.4M
$1.2B
Q2 25
$437.4M
$1.2B
Q1 25
$462.8M
$1.2B
Q4 24
$467.1M
$1.2B
Q3 24
$506.7M
$985.3M
Q2 24
$484.1M
$987.4M
Q1 24
$518.7M
$988.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTRN
CTRN
ZLAB
ZLAB
Operating Cash FlowLast quarter
$8.6M
$-26.0M
Free Cash FlowOCF − Capex
$767.0K
$-26.7M
FCF MarginFCF / Revenue
0.4%
-21.0%
Capex IntensityCapex / Revenue
4.0%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$11.9M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTRN
CTRN
ZLAB
ZLAB
Q4 25
$8.6M
$-26.0M
Q3 25
$3.9M
$-32.0M
Q2 25
$-11.0M
$-31.0M
Q1 25
$28.5M
$-61.7M
Q4 24
$-18.4M
$-55.8M
Q3 24
$5.6M
$-26.8M
Q2 24
$-19.6M
$-42.2M
Q1 24
$23.3M
$-90.1M
Free Cash Flow
CTRN
CTRN
ZLAB
ZLAB
Q4 25
$767.0K
$-26.7M
Q3 25
$-1.7M
$-35.0M
Q2 25
$-13.1M
$-33.9M
Q1 25
$26.0M
$-63.2M
Q4 24
$-20.4M
$-58.4M
Q3 24
$1.7M
$-28.2M
Q2 24
$-21.2M
$-42.9M
Q1 24
$20.0M
$-91.1M
FCF Margin
CTRN
CTRN
ZLAB
ZLAB
Q4 25
0.4%
-21.0%
Q3 25
-0.9%
-30.4%
Q2 25
-6.5%
-31.1%
Q1 25
12.3%
-59.9%
Q4 24
-11.4%
-53.8%
Q3 24
0.9%
-27.7%
Q2 24
-11.4%
-42.9%
Q1 24
9.3%
-104.5%
Capex Intensity
CTRN
CTRN
ZLAB
ZLAB
Q4 25
4.0%
0.5%
Q3 25
2.9%
2.6%
Q2 25
1.0%
2.6%
Q1 25
1.2%
1.5%
Q4 24
1.1%
2.4%
Q3 24
2.2%
1.3%
Q2 24
0.9%
0.7%
Q1 24
1.5%
1.1%
Cash Conversion
CTRN
CTRN
ZLAB
ZLAB
Q4 25
Q3 25
1.01×
Q2 25
-12.59×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
6.56×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTRN
CTRN

Segment breakdown not available.

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons